SCHEMBL3073642

SCHEMBL3073642

O=C(O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.49
AKR1C1 Q04828 1/20 0.49
CTSS P25774 3/20 0.48
MCL1 Q07820 1/20 0.46
MME P08473 1/20 0.44
ACE P12821 1/20 0.44
ECE1 P42892 1/20 0.44
CCR4 P51679 2/20 0.43
EIF2AK3 Q9NZJ5 1/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
CTSL P07711 2/20 0.42
CTSB P07858 2/20 0.42
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
MMP9 P14780 3/20 0.41
CA12 O43570 2/20 0.41
CA2 P00918 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3061047 0.87 CTSS (0.49) CTSSCTSLCTSBALDH1A1
SCHEMBL3721649 0.86 CA12 (0.50) CTSSCTSLCTSBMMP9CA12
SCHEMBL3060736 0.86 CA12 (0.50) CTSSCTSLCTSBMMP9CA12
SCHEMBL695696 0.82 CTSS (0.65) CTSSCTSLCTSB
SCHEMBL6945225 0.79 AKR1C3 (0.54) AKR1C3AKR1C1MCL1MMEACE
SCHEMBL5415726 0.79 AKR1C3 (0.54) AKR1C3AKR1C1MCL1MMEACE
SCHEMBL6977959 0.78 ECE1 (0.62) AKR1C3AKR1C1MCL1MMEACE
SCHEMBL7141433 0.78 ECE1 (0.62) AKR1C3AKR1C1MCL1MMEACE
SCHEMBL7138285 0.78 AKR1C3 (0.52) AKR1C3AKR1C1MCL1MMEACE
SCHEMBL7141900 0.78 AKR1C3 (0.52) AKR1C3AKR1C1MCL1MMEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 AKR1C3 567/4885AKR1C1 444/4885CTSS 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.